Product Center
Breaking through Bottleneck Technology, Significant Progress has been Made in the Research and Development of New Adjuvants
- Categories:Company news
- Author:
- Origin:
- Time of issue:2024-08-26
- Views:
(Summary description)On August 25th, the R&D team of Yither Biotech (Shanghai) Co., Ltd., a wholly-owned subsidiary of Ab&B Bio-Tech Co., Ltd. (Ab&B Bio), made a breakthrough in the field of innovative adjuvant research and development. The research results were published online in the internationally renowned journal Journal of Drug Delivery Science and Technology under the title "Dual functional Emulsifier-Based Nanoemulsification Adjuvant Effectively Enhanced Immunogenicity of Recombinant Respiratory Syncytial Virus Vaccine in Mice".
Breaking through Bottleneck Technology, Significant Progress has been Made in the Research and Development of New Adjuvants
(Summary description)On August 25th, the R&D team of Yither Biotech (Shanghai) Co., Ltd., a wholly-owned subsidiary of Ab&B Bio-Tech Co., Ltd. (Ab&B Bio), made a breakthrough in the field of innovative adjuvant research and development. The research results were published online in the internationally renowned journal Journal of Drug Delivery Science and Technology under the title "Dual functional Emulsifier-Based Nanoemulsification Adjuvant Effectively Enhanced Immunogenicity of Recombinant Respiratory Syncytial Virus Vaccine in Mice".
- Categories:Company news
- Author:
- Origin:
- Time of issue:2024-08-26 18:05
- Views:
On August 25th, the R&D team of Yither Biotech (Shanghai) Co., Ltd., a wholly-owned subsidiary of Ab&B Bio-Tech Co., Ltd. (Ab&B Bio), made a breakthrough in the field of innovative adjuvant research and development. The research results were published online in the internationally renowned journal Journal of Drug Delivery Science and Technology under the title "Dual functional Emulsifier-Based Nanoemulsification Adjuvant Effectively Enhanced Immunogenicity of Recombinant Respiratory Syncytial Virus Vaccine in Mice".
Subunit vaccines, genetically engineered vaccines, etc. usually require the addition of adjuvants to enhance their immunogenicity and activate effective immune responses. However, the number of components in a vaccine is not necessarily better, and adjuvants that combine delivery and immune stimulation functions are the most ideal. Therefore, the company's R&D team targeted different types of immune responses, combined with the structural characteristics of immune stimulators, while ensuring safety, and took the lead in using emulsifiers with immune stimulatory functions to develop efficient preparation processes and unique nanoemulsion adjuvants. The results of animal experiments show that the use of this adjuvant, combined with our self-developed recombinant protein antigen, can effectively stimulate the body's humoral and cellular immune responses. Compared with MF59 and aluminum/CpG adjuvant systems, it exhibits significant advantages. Currently, the adjuvant can achieve GMP production, and the invention patent for "a nanoemulsion adjuvant (application number 2023103883104)" based on the adjuvant application has also entered the substantive examination stage.
Ab&B Bio actively expands into the field of innovative adjuvants, focusing on the research and development of "nano adjuvant formulations, new immunostimulants, and composite adjuvant systems". Based on antigen characteristics, it develops its exclusive adjuvants and production processes, aiming to efficiently enhance the body's immune response, reduce the risk of adverse reactions, and reduce the amount of antigen used. The company is independently developing multiple adjuvants and gradually applying them to innovative products such as pneumococcal polysaccharide conjugate vaccines, recombinant herpes zoster vaccines, and recombinant respiratory syncytial virus vaccines, providing an "acceleration" for the company's innovative vaccine production.
Relevant information
-
The world's first! The monkeypox mRNA vaccine has obtained dual clinical trial approvals from both China and the United States.Recently, the IND application for a Class 1 new drug, the "Monkeypox mRNA vaccine," jointly submitted by Ab&B Bio-Tech CO.,LTD.JS (Ab&B Bio) and its subsidiary Yither Biotech CO., Ltd (Yither Bio), was approved by the Center for Drug Evaluation (CDE) of the China National Medical Products Administration. - Phase I/II Clinical Trial of the Re engineered Respiratory Syncytial Virus Vaccine (CHO Cells)(Adjuvant)Officially Launched 05-13
- The mRNA technology platform has achieved another milestone, with global innovation efforts accelerating. 05-08
- Our innovative vaccine research team won the 20th "Jiangsu Youth May Fourth Medal Collective" award 04-27
- The Ab&B Bio Promotion Business Conference and 10th Anniversary Celebration were successfully held 04-25
Got a project? Contact us today !
At Ab&B Bio, our mission is to care for life and protect health by developing globally innovative vaccines.
Contact
E-mail:haixin.zhang@yitherbiotech.com
Add:No. 32, Xinglin Road, Medical High-tech Zone, Taizhou City
Quick view
Follow us
